ARVINAS, INC.

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for debilitating and life-threatening diseases. The company utilizes its PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform to develop a new class of therapeutics. These therapeutics are designed to use the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas has developed and optimized its proprietary PROTAC Discovery Engine to identify PROTAC therapeutics for diseases caused by abnormal proteins or aberrant protein expression. The company believes its targeted protein degradation approach is a novel therapeutic modality that may offer advantages over existing therapies and target a broad range of proteins, including those previously considered undruggable. Over the past five years, seven programs developed using Arvinas's PROTAC protein degradation platform have advanced to clinical trials in oncology and neurology indications, following preclinical studies demonstrating potent and selective protein degradation. The U.S. Food and Drug Administration, or FDA, has accepted the company's New Drug Application, or NDA, for vepdegestrant, its most advanced product candidate from the platform. Vepdegestrant is intended for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), or ER+/HER2-, estrogen receptor 1, or ESR1,-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 5, 2026, for vepdegestrant.